Company Overview - CorMedix (CRMD) shares increased by 5.1% to close at $11.62, following a notable trading volume compared to typical sessions, despite a 29.6% loss over the past four weeks [1] - The rise in stock price is linked to growing investor optimism regarding the initial sales uptake of DefenCath, the company's lead product, which received FDA approval in November 2023 as the first catheter lock solution [2] Earnings Expectations - CorMedix is projected to report quarterly earnings of $0.17 per share, reflecting a year-over-year increase of +168%, with revenues expected to reach $36.2 million, a staggering increase of 4369.1% from the same quarter last year [3] - The consensus EPS estimate for CorMedix has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - CorMedix operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Illumina (ILMN), saw a 2.5% increase in stock price, closing at $104.61, and has returned 11.5% over the past month [5] - Illumina's consensus EPS estimate for its upcoming report has decreased by -0.2% to $1.02, representing a year-over-year change of +183.3% [6]